Giredestrant Plus Everolimus Just Cleared the Bar: What the evERA Data Actually Demands From Trial Designers
NEJM publishes evERA Breast Cancer trial data showing giredestrant plus everolimus superiority in HR+ advanced breast cancer, here's what...
The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.
WILLOW Cohort B's p=0.14 masked a 58% BICLA response at the lowest dose. The drug worked. The endpoint couldn't...
The EPoS II Trial Just Made the 3-Year Colonoscopy Standard Look Like a Reflex, Not a Rule
EPoS II RCT finds 5-year colonoscopy surveillance noninferior to 3-year for high-risk adenoma patients, forcing a rethink of global...
The RIO Trial’s Viral Rebound Data Just Complicated Every HIV Functional Cure Strategy on the Market
Phase 2 RIO trial shows 3BNC117-LS and 10-1074-LS delay HIV viral rebound after treatment interruption, but resistance patterns raise...
Mitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here’s What the ENERGIZE-T Data Actually Mean
ENERGIZE-T's Phase 3 data shows mitapivat cut transfusion burden in 258 thalassaemia patients. Here's what the trial design reveals...
The Algorithm Passed Every Benchmark. The Patients Didn’t Notice.
A landmark Nature Medicine RCT found AI improved clinician decisions but not patient outcomes, exposing the fatal flaw in...
NSABP B-59 Failed. The Real Question Is Why We Keep Designing Trials That Can’t Detect the Signal.
The NSABP B-59/GeparDouze trial enrolled 1,550 TNBC patients and missed its primary endpoint. Atezolizumab's Phase 3 failure reveals a...
Dubai’s rWGS Scale-Up Rewrites the Diagnostic Playbook — But the Data Infrastructure Problem Stays Unsolved
Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf standard testing, but exposes...
Psilocybin Works in the Lab. Can It Survive the Clinic?
A UK NHS psilocybin trial exposes the standardization gap threatening psychedelic drug approval — therapist training, setting protocols, and...
Upadacitinib’s Phase 3 Vitiligo Data Just Redrew the Regulatory Map for JAK Inhibitors in Dermatology
AbbVie's Viti-Up trials showed upadacitinib 15mg hit F-VASI 75 in vitiligo across two Phase 3 studies—here's what the trial...